Skip to main content

Advertisement

Log in

A Systematic Review of Esophageal MicroRNA Markers for Diagnosis and Monitoring of Barrett’s Esophagus

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Esophageal epithelial microRNAs may be used to diagnose Barrett’s esophagus (BE) and possibly monitor its progression to esophageal adenocarcinoma (EAC).

Aims

We reviewed studies that have investigated this to identify microRNAs with high biomarker potential for screening and disease monitoring in BE.

Methods

PubMed and EMBASE databases were searched for studies that quantified esophageal epithelial microRNAs. Publications reporting microRNA comparisons of normal, non-dysplastic BE, BE with high-grade dysplasia (HGD), and EAC tissues using both unbiased discovery and independent validation phases were reviewed.

Results

Eleven studies on microRNA expression differences between normal epithelium and non-dysplastic BE (seven studies), HGD (4) or EAC (7), or between non-dysplastic BE and HGD (3) or EAC (6) were identified, and the findings of their validation phase were analyzed. Increased miR-192, -194, and -215, and reduced miR-203 and -205 expression in BE compared to normal was noticed by all 4–6 of the seven studies that examined these microRNAs. In heterogeneity tests of the reported fold-change values, the I 2 statistics were 7.9–17.1 % (all P < 0.05). Elevated miR-192, -194, and -215, and diminished miR-203 and -205 levels were also noted for comparisons of HGD or EAC against normal. In contrast, a consistent microRNA expression difference was absent for the comparisons of HGD or EAC against BE.

Conclusions

MicroRNAs miR-192, -194, -203, -205, and -215 are promising tissue biomarkers for diagnosing BE. Cross-sectional data suggest that microRNAs may have a limited role in separating BE from HGD/EAC epithelia but need further testing in longitudinal follow-up studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

BE:

Barrett’s esophagus

EAC:

Esophageal adenocarcinoma

GERD:

Gastroesophageal reflux disease

HGD:

High-grade dysplasia

References

  1. Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119:1149–1158.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Prasad GA, Wu TT, Wigle DA, et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett’s esophagus. Gastroenterology. 2009;137:815–823.

    Article  PubMed  Google Scholar 

  3. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360:2277–2288.

    Article  CAS  PubMed  Google Scholar 

  4. Shaheen NJ, Hur C. Garlic, silver bullets, and surveillance upper endoscopy for Barrett’s esophagus. Gastroenterology. 2013;145:273–276.

    Article  PubMed  Google Scholar 

  5. Spechler SJ, Souza RF. Barrett’s esophagus. N Engl J Med. 2014;371:836–845.

    Article  CAS  PubMed  Google Scholar 

  6. Sharma P. Clinical practice. Barrett’s esophagus. N Engl J Med. 2009;361:2548–2556.

    Article  CAS  PubMed  Google Scholar 

  7. Reid BJ. Early events during neoplastic progression in Barrett’s esophagus. Cancer Biomark. 2010;9:307–324.

    PubMed  PubMed Central  Google Scholar 

  8. Prasad GA, Bansal A, Sharma P, Wang KK. Predictors of progression in Barrett’s esophagus: current knowledge and future directions. Am J Gastroenterol. 2010;105:1490–1502.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Theisen J, Stein HJ, Dittler HJ, et al. Preoperative chemotherapy unmasks underlying Barrett’s mucosa in patients with adenocarcinoma of the distal esophagus. Surg Endosc. 2002;16:671–673.

    Article  CAS  PubMed  Google Scholar 

  10. Ross-Innes CS, Debiram-Beecham I, O’Donovan M, et al. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett’s esophagus: a multi-center case–control study. PLoS Med. 2015;12:e1001780.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Kastelein F, Biermann K, Steyerberg EW, et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett’s oesophagus. Gut. 2013;62:1676–1683.

    Article  CAS  PubMed  Google Scholar 

  12. Lujambio A, Lowe SW. The microcosmos of cancer. Nature. 2012;482:347–355.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–838.

    Article  CAS  PubMed  Google Scholar 

  14. Saito M, Shiraishi K, Matsumoto K, et al. A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma. Clin Cancer Res. 2014;20:4784–4793.

    Article  CAS  PubMed  Google Scholar 

  15. Bansal A, Lee IH, Hong X, et al. Feasibility of microRNAs as biomarkers for Barrett’s esophagus progression: a pilot cross-sectional, phase 2 biomarker study. Am J Gastroenterol. 2011;106:1055–1063.

  16. Smith CM, Michael MZ, Watson DI, et al. Impact of gastro-oesophageal reflux on microRNA expression, location and function. BMC Gastroenterol. 2013;13:4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Bansal A, Lee IH, Hong X, et al. Discovery and validation of Barrett’s esophagus microRNA transcriptome by next generation sequencing. PLoS ONE. 2013;8:e54240.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Fassan M, Volinia S, Palatini J, et al. MicroRNA expression profiling in human Barrett’s carcinogenesis. Int J Cancer. 2011;129:1661–1670.

  19. Fassan M, Volinia S, Palatini J, et al. MicroRNA expression profiling in the histological subtypes of Barrett’s metaplasia. Clin Transl Gastroenterol. 2013;4:e34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Feber A, Xi L, Luketich JD, et al. MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg. 2008;135:255–260. (discussion 260).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Wu X, Ajani JA, Gu J, et al. MicroRNA expression signatures during malignant progression from Barrett’s esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila). 2013;6:196–205.

    Article  CAS  Google Scholar 

  22. Garman KS, Owzar K, Hauser ER, et al. MicroRNA expression differentiates squamous epithelium from Barrett’s esophagus and esophageal cancer. Dig Dis Sci. 2013;58:3178–3188.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Kan T, Meltzer SJ. MicroRNAs in Barrett’s esophagus and esophageal adenocarcinoma. Curr Opin Pharmacol. 2009;9:727–732.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Kan T, Sato F, Ito T, et al. The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterology. 2009;136:1689–1700.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Leidner RS, Ravi L, Leahy P, et al. The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett’s esophageal carcinogenesis. Genes Chromosomes Cancer. 2012;51:473–479.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Luzna P, Gregar J, Uberall I, Radova L, Prochazka V, Ehrmann J Jr. Changes of microRNAs-192, 196a and 203 correlate with Barrett’s esophagus diagnosis and its progression compared to normal healthy individuals. Diagn Pathol. 2011;6:114.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Maru DM, Singh RR, Hannah C, et al. MicroRNA-196a is a potential marker of progression during Barrett’s metaplasia–dysplasia–invasive adenocarcinoma sequence in esophagus. Am J Pathol. 2009;174:1940–1948.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Mathe EA, Nguyen GH, Bowman ED, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res. 2009;15:6192–6200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Matsuzaki J, Suzuki H, Tsugawa H, et al. Bile acids increase levels of microRNAs 221 and 222, leading to degradation of CDX2 during esophageal carcinogenesis. Gastroenterology. 2013;145:1300–1311.

    Article  CAS  PubMed  Google Scholar 

  30. Revilla-Nuin B, Parrilla P, Lozano JJ, et al. Predictive value of microRNAs in the progression of Barrett esophagus to adenocarcinoma in a long-term follow-up study. Ann Surg. 2013;257:886–893.

    Article  PubMed  Google Scholar 

  31. van Baal JW, Verbeek RE, Bus P, et al. MicroRNA-145 in Barrett’s oesophagus: regulating BMP4 signalling via GATA6. Gut. 2012;62:664–675.

  32. Wijnhoven BP, Hussey DJ, Watson DI, Tsykin A, Smith CM, Michael MZ. MicroRNA profiling of Barrett’s oesophagus and oesophageal adenocarcinoma. Br J Surg. 2010;97:853–861.

    Article  CAS  PubMed  Google Scholar 

  33. Yang H, Gu J, Wang KK, et al. MicroRNA expression signatures in Barrett’s esophagus and esophageal adenocarcinoma. Clin Cancer Res. 2009;15:5744–5752.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Saad R, Chen Z, Zhu S, et al. Deciphering the unique microRNA signature in human esophageal adenocarcinoma. PLoS ONE. 2013;8:e64463.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180–1184.

    Article  CAS  PubMed  Google Scholar 

  36. Altman DG, Bland JM. How to obtain the confidence interval from a P value. BMJ. 2011;343:d2090.

    Article  PubMed  Google Scholar 

  37. Streppel MM, Pai S, Campbell NR, et al. MicroRNA 223 is upregulated in the multistep progression of Barrett’s esophagus and modulates sensitivity to chemotherapy by targeting PARP1. Clin Cancer Res. 2013;19:4067–4078.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Chen Z, Saad R, Jia P, et al. Gastric adenocarcinoma has a unique microRNA signature not present in esophageal adenocarcinoma. Cancer. 2013;119:1985–1993.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med. 2012;9:e1001216.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93:1054–1061.

    Article  CAS  PubMed  Google Scholar 

  41. Smith E, De Young NJ, Pavey SJ, et al. Similarity of aberrant DNA methylation in Barrett’s esophagus and esophageal adenocarcinoma. Mol Cancer. 2008;7:75.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Meyer SU, Pfaffl MW, Ulbrich SE. Normalization strategies for microRNA profiling experiments: a ‘normal’ way to a hidden layer of complexity? Biotechnol Lett. 2010;32:1777–1788.

    Article  CAS  PubMed  Google Scholar 

  43. Slaby O, Srovnal J, Radova L, et al. Dynamic changes in microRNA expression profiles reflect progression of Barrett’s esophagus to esophageal adenocarcinoma. Carcinogenesis. 2015;36:521–527.

    Article  PubMed  Google Scholar 

  44. Lee IH, Hong X, Mathur SC, et al. A detailed analysis of next generation sequencing reads of microRNA expression in Barrett’s esophagus: absolute versus relative quantification. BMC Res Notes. 2014;7:212.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Ozsolak F, Milos PM. RNA sequencing: advances, challenges and opportunities. Nat Rev Genet. 2011;12:87–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Nones K, Waddell N, Wayte N, et al. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat Commun. 2014;5:5224.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Rugge M, Zaninotto G, Parente P, et al. Barrett’s esophagus and adenocarcinoma risk: the experience of the North-Eastern Italian Registry (EBRA). Ann Surg. 2012;256:788–794. (discussion 794-785).

    Article  PubMed  Google Scholar 

  48. Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2006;4:566–572.

    Article  PubMed  Google Scholar 

  49. Reid BJ, Sanchez CA, Blount PL, Levine DS. Barrett’s esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology. 1993;105:119–129.

    CAS  PubMed  Google Scholar 

  50. Kadri SR, Lao-Sirieix P, O’Donovan M, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett’s oesophagus in primary care: cohort study. BMJ. 2010;341:c4372.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Abrams JA, Appelman HD, Beer DG, et al. Barrett’s Esophagus Translational Research Network (BETRNet): the pivotal role of multi-institutional collaboration in esophageal adenocarcinoma research. Gastroenterology. 2014;146:1586–1590.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Chiam K, Wang T, Watson DI, et al. Circulating serum exosomal miRNAs as potential biomarkers for esophageal adenocarcinoma. J Gastrointest Surg. 2015;19:1208–1215.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Junior Faculty Career Development Award from the American College of Gastroenterology to A. B.

Author contributions

A. B. conceived and designed the study. All authors contributed to data collection and analysis, and approved the submitted manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ajay Bansal.

Ethics declarations

Conflict of interest

None.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Table 1

PRISMA 2009 checklist (DOC 55 kb)

Supplementary Table 2

Quality assessment of the reviewed studies using REMARK criteria (DOC 57 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mallick, R., Patnaik, S.K., Wani, S. et al. A Systematic Review of Esophageal MicroRNA Markers for Diagnosis and Monitoring of Barrett’s Esophagus. Dig Dis Sci 61, 1039–1050 (2016). https://doi.org/10.1007/s10620-015-3959-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-015-3959-3

Keywords

Navigation